Nitric oxide signaling plays a key role in the regulation of vascular tone and platelet activation. Here, we seek to understand the impact of a genetic predisposition to enhanced nitric oxide signaling on risk for cardiovascular diseases, thus informing the potential utility of pharmacological stimulation of the nitric oxide pathway as a therapeutic strategy.
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ORIGINAL RESEARCH ARTICLE N itric oxide signaling is a key regulator of vascular tone, blood pressure, and platelet aggregation. 1, 2 Endothelial nitric oxide synthase, encoded by the gene NOS3, generates nitric oxide in the vascular endothelium ( Figure 1) . 3 Nitric oxide acts as a signaling molecule to activate soluble guanylyl cyclase, a heterodimeric protein with 1 subunit encoded by the gene GUCY1A3. 3, 4 Cyclic guanosine monophosphate produced by soluble guanylyl cyclase then activates downstream signaling molecules, leading to vasodilation, blood pressure lowering, inhibition of platelet aggregation, and other cardiometabolic effects. 5, 6 NOS3 and GUCY1A3 are thus key mediators of nitric oxide signaling and its downstream effects ( Figure 1 ).
Previous studies have noted increased blood pressure and atherosclerotic burden in endothelial nitric oxide synthase -/-knockout mice, 7, 8 whereas loss of soluble guanylyl cyclase promotes thrombus formation. 9 Common noncoding variants in the NOS3 and GUCY1A3 loci associate with blood pressure and coronary heart disease (CHD) in genome-wide association studies, consistent with a role of nitric oxide signaling in the regulation of arterial blood pressure. [10] [11] [12] Furthermore, a rare coding variant in GUCY1A3 was identified as associating with early onset myocardial infarction in a German family. 9 These findings in mice and humans suggest that stimulation of nitric oxide signaling may be a useful therapeutic strategy for the prevention of cardiovascular diseases.
DNA sequence variants in therapeutic target genes represent naturally occurring, lifelong variation of the gene (ie, experiments of nature). Consequently, if a genetic predisposition to enhanced nitric oxide signaling associates with a reduced risk of cardiovascular and other diseases, these results would support the therapeutic hypothesis that pharmacological stimulation of nitric oxide signaling (eg, through soluble guanylyl cyclase stimulation 13 ) will prevent or treat cardiovascular disease. Furthermore, if the association of nitric oxide signaling with CHD risk is partially mediated through blood pressureindependent pathways, stimulation of nitric oxide signaling may represent an approach for CHD prevention independent of current blood pressure-lowering therapies.
We therefore sought to use common and rare DNA sequence variants in NOS3 and GUCY1A3 to: (1) determine the effects of a genetic predisposition to enhanced nitric oxide signaling on a range of cardiometabolic and other diseases, (2) assess whether the effect of nitric oxide signaling on CHD is primarily mediated through blood pressure, and (3) determine whether rare inactivating variants in NOS3 and GUCY1A3 that are predicted to reduce nitric oxide signaling associate with higher risk for CHD.
METHODS
The data, analytic methods, and study materials are available to other researchers for the purposes of reproducing the results or replicating the procedure, with access maintained by UK Biobank.
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Study Design, Data Sources, and Study Participants
The study design is shown in Figure I in the online-only Data Supplement. We used individual-level data from 335 464 individuals of European ancestry from the UK Biobank, a large population-based cohort (Methods A in the online-only Data Supplement). Characteristics of individuals in UK Biobank are provided (Table I in the online-only Data Supplement). We supplemented this individual-level data with 7 genomewide association study consortia examining blood lipids, anthropometric traits, glycemic traits, diabetes mellitus, CHD, migraine, and renal dysfunction, all predominantly containing individuals of European descent (Methods B and Table II in the online-only Data Supplement). Finally, we used gene sequence data from 27 815 participants from the Myocardial Infarction Genetics Consortium and 16 857 participants from the T2D GENES study (Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples) 15 to examine whether rare variants in the NOS3-GUCY1A3 pathway associate with blood pressure and CHD (Methods C in the online-only Data Supplement).
In our primary analysis, we examined the effect of a genetic predisposition to enhanced nitric oxide signaling on 9 different cardiometabolic diseases: CHD, stroke, heart failure, atrial fibrillation, aortic stenosis, peripheral vascular disease, venous thromboembolism, diabetes mellitus, and chronic kidney disease (Table III in the online-only Data Supplement). We additionally examined the effect of a genetic predisposition to enhanced nitric oxide signaling on 16 quantitative traits (Methods A and B in the online-only Data Supplement): systolic blood pressure, diastolic blood pressure, waist-to-hip ratio adjusted for body mass index, 16 body mass index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting glucose, fasting
Clinical Perspective
What Is New?
• A genetic predisposition to enhanced nitric oxide signaling, as mediated by common variants in the NOS3 and GUCY1A3 genes, was associated with lower blood pressure and a reduced risk of coronary heart disease, peripheral arterial disease, and stroke.
• Rare variants that inactivate either the NOS3 or GUCY1A3 gene were associated with increased blood pressure and a higher risk of coronary heart disease.
What Are the Clinical Implications?
• The results suggest that the pharmacological stimulation of nitric oxide signaling may be an effective therapy for the prevention or treatment of atherosclerotic cardiovascular disease.
insulin, 2-hour glucose, hemoglobin A1C, serum creatinineestimated glomerular filtration rate, cystatin-C-estimated glomerular filtration rate, forced expiratory volume in 1 second, and the ratio of forced expiratory volume in 1 second to forced vital capacity. 
Common Variants in NOS3 and GUCY1A3
We leveraged common variants in the NOS3 and GUCY1A3 loci to characterize the effects of a genetic predisposition to enhanced nitric oxide signaling. Two common variants were selected as instruments for a genetic predisposition to enhanced nitric oxide signaling: a promoter variant of NOS3 (rs3918226; minor allele frequency 8%) and an intronic variant of GUCY1A3 (rs7692387; minor allele frequency 19%) (Table IV in the online-only Data Supplement). These variants were selected because they: (1) have been robustly associated with blood pressure (a downstream effect of nitric oxide signaling); and (2) are located within the endothelial nitric oxide synthase-soluble guanylyl cyclase signaling pathway. 17, 18 Furthermore, the minor allele of rs7692387 has also recently been characterized to reduce GUCY1A3 expression via disruption of a ZEB1 transcription factor site. 19 We examined the effect of these variants on NOS3 and GUCY1A3 expression levels in aortic and lung tissue in the Genotype-Tissue Expression project database 20 (Methods D in the online-only Data Supplement) and the effect of these variants on mean arterial pressure in the UK Biobank.
To examine the effects of increased nitric oxide signaling on cardiometabolic and other traits, we pooled rs3918226 and rs7692387 into an additive genetic score (individuals had 0-4 risk alleles). We derived this score by multiplying the number of risk alleles by the association of each allele with mean arterial pressure in the UK Biobank (0.68 mm Hg for rs3918226 and 0.32 mm Hg for rs7692387). For example, if an individual had 2 risk alleles for rs3918226 and 1 risk allele for rs7692387, the genetic score was calculated as 2*0.68 mm Hg + 0.32 mm Hg = 1.68 mm Hg. Individuals missing 1 variant (either rs3918226 or rs7692387; n=6036 [1.8%]) were imputed at the mean allele frequency for the variant prior to calculation of the genetic score. We standardized the nitric oxide signaling genetic score to a 5 mm Hg reduction in mean arterial pressure, corresponding to the effect of 1.5 mg of riociguat (a pharmacological stimulator of soluble guanylate cyclase) on mean arterial pressure in a recent randomized controlled trial. 13 The standardization was performed by dividing the genetic nitric oxide score by 5 mm Hg (eg, 1.68 mm Hg/5 mm Hg=0.34). We also report estimates standardized to a 2.5 mm Hg and 10 mm Hg lower mean arterial pressure to clarify the expected reduction in risk of cardiometabolic outcomes with different levels of nitric oxide signaling.
Rare Predicted Loss-of-Function Variants in NOS3 and GUCY1A3
Common noncoding variants may influence the expression of several nearby genes. 21 Therefore, to provide complementary 
ORIGINAL RESEARCH ARTICLE
evidence that the NOS3-GUCY1A3 pathway influences blood pressure and CHD risk, we examined whether rare (minor allele frequency <1%) predicted loss-of-function variants in NOS3 and GUCY1A3 are associated with systolic blood pressure, diastolic blood pressure, and CHD (Methods C in the online-only Data Supplement). Predicted loss-of-function variants were defined as: (1) insertions or deletions of DNA that modify the reading frame of protein translation (frameshift); (2) point mutations at conserved splice site regions that alter the splicing process (splice-site); or (3) point mutations that change an amino acid codon to a stop codon, leading to the truncation of a protein (nonsense).
For blood pressure, we tested whether presence of a predicted loss-of-function variant in NOS3 and GUCY1A3 was associated with systolic blood pressure or diastolic blood pressure in the T2D GENES study (n=16 857). We examined whether predicted loss-of-function variants were associated with systolic and diastolic blood pressure using the Genetic Association Interactive Tool on the Type 2 Diabetes Knowledge Portal. 15 We used linear regression and adjusted for age, sex, and 5 principal components of ancestry.
For CHD, we tested whether presence of a predicted loss-of-function variant was associated with CHD in the Myocardial Infarction Genetics Consortium (n=27 815) study using logistic regression, adjusted for sex, 5 principal components of ancestry, and a dummy variable for each cohort. To examine whether variants in the NOS3-GUCY1A3 pathway associate with CHD risk, we pooled the effect of predicted loss-of-function variants in NOS3 and GUCY1A3 on CHD using inverse variance weighted fixed effects meta-analysis.
Statistical Analysis
For the UK Biobank, we estimated the association of the nitric oxide signaling genetic score (standardized to a 5 mm Hg decrease in mean arterial pressure) with each outcome using a logistic regression model adjusting for age, sex, 10 principal components of ancestry, and a dummy variable for array type. For the summary-level data, this approach is equivalent to an inverse variance weighted fixed effects meta-analysis of the effect of each variant on traits or outcome of interest per 5 mm Hg lower mean arterial pressure. Tests for interaction between UK Biobank and summary-level estimates were calculated as the difference in log-transformed relative risks, as previously described. 22 For our primary outcomes (9 cardiometabolic diseases), we set a Bonferroni adjusted level of significance of P=0.05/9=0.0056. For our secondary analyses of 16 cardiometabolic and pulmonary traits and our phenome-wide association study of 26 phenotypes, we set a level of significance of P=0.05/42=0.001.
To examine whether an observed reduction in risk of CHD was caused by reduced blood pressure, a mediation analysis was conducted. An estimate of the causal effect of systolic blood pressure on CHD risk was derived from a recent genome-wide association study (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.17-1.24 per 5 mm Hg higher systolic blood pressure) (Methods E in the online-only Data Supplement). 11 This effect was then multiplied by the decrease in systolic blood pressure because of nitric oxide signaling to estimate the decrease in CHD risk mediated by systolic blood pressure. We then subtracted this estimate from the overall estimate of the nitric oxide genetic score with CHD to derive the remaining proportion of CHD risk unaccounted for by a decrease in systolic blood pressure. For example, if the odds ratio for CHD for the genetic score was 0.5 but the odds ratio for CHD from the systolic blood pressure decrease was 0.75, the OR for CHD independent of systolic blood pressure was calculated as exp(log(0.5) -log(0.75))=0.67.
All analyses were performed using R version 3.2.3 software (The R Project for Statistical Computing).
RESULTS
In the Genome Tissue Expression project database, 20 the C allele of rs3918226 was associated with increased NOS3 expression in lung tissue (48% higher expression; P=0.002) but was not significantly associated with NOS3 expression in aortic tissue (23% higher expression; P=0.21) (Figure 2 ). The A allele of rs7692387 was associated with increased GUCY1A3 expression in aortic tissue (20% higher expression; P=0.012) but was not significantly associated with GUCY1A3 expression in lungs (7% higher expression, P=0.20). As expected for variants that enhance nitric oxide signaling, both rs3918226 and rs7692387 were associated with lower mean arterial pressure among UK Biobank participants , respectively) (Figure 2 ), replicating previously reported associations of these variants with blood pressure at genome-wide significance. 17, 18 When combined into a nitric oxide-signaling genetic score and standardized to a 5 mm Hg reduction in mean arterial pressure, a genetic predisposition to enhanced nitric oxide signaling was nominally associated with improved renal function, as assessed by both cystatin C-estimated glomerular filtration rate (7.6 mL/ min; 95% CI, 2.9-12 mL/min; P=0.0015) and creatinine-estimated glomerular filtration rate (2.8 mL/min; 95% CI, 0.57-5.1 mL/min; P=0.014) (Figure 3) .
Enhanced nitric oxide signaling was significantly associated with higher forced expiratory volume in 1 second (0.09 L; 95% CI, 0.05-0.12; P=5.6*10
). We examined whether the association of a genetic predisposition to enhanced nitric oxide signaling with pulmonary function differed by baseline pulmonary function. No evidence of a trend by baseline pulmonary function for forced expiratory volume in 1 second was observed (P=0.34, respectively) ( Figure II in the online-only Data Supplement). Enhanced nitric oxide signaling was not significantly associated with any other cardiometabolic traits, including glycemic traits or blood lipids (Figure 3) .
The genetic nitric oxide signaling score was significantly associated with 3 of the 9 primary cardiometabolic outcomes. A genetic predisposition to enhanced nitric oxide signaling was associated with reduced risk Association of rs3918226 and rs7692387 with (A) NOS3 or GUCY1A3 expression levels in aortic and lung tissue, and (B) mean arterial pressure among UK Biobank participants. Effect of variants on expression levels were obtained from the Genotype-Tissue Expression project. Effect of variants on mean arterial pressure were derived in the UK Biobank using linear regression adjusted for age, sex, 10 principal components of ancestry, and array type (least squares means estimates). rs3918226 was associated with significantly elevated NOS3 expression in the lung. rs7692387 was associated with significantly elevated GUCY1A3 expression in the aorta. MAP indicates mean arterial pressure.
Figure 3. Association of the nitric oxide signaling genetic score with cardiometabolic traits (secondary outcomes).
BMI indicates body mass index; eGFRcrea, serum creatinine-estimated glomerular filtration rate; eGFRcys, cystatin-C-estimated glomerular filtration rate; DBP, diastolic blood pressure; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HbA1c, hemoglobin A1c; HDL cholesterol, high-density lipoprotein cholesterol; LDL cholesterol, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; and WHRadjBMI, waist-to-hip ratio adjusted for body mass index. P values that reach a Bonferroni-adjusted level of statistical significance (P<0.001) are in boldface.
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95% CI, 0.67-0.99; P=0.037). In a phenome-wide association study of 26 different diseases, enhanced nitric oxide signaling was not significantly associated with any other disease, including a variety of gastrointestinal diseases, musculoskeletal diseases, and cancers ( Figure 4) . In sensitivity analyses, when standardized to a 2.5 or 10 mm Hg lower mean arterial reduction, the nitric oxide signaling genetic score was associated with a 39% (OR, 0.61; 95% CI, 0.56-0.67) and 86% lower risk of CHD (OR, 0.14; 95% CI, 0.10-0.20), respectively (Figure IV in the online-only Data Supplement).
When an interaction term between the NOS3 and GUCY1A3 genetic loci was included, no evidence of an interaction in the association of nitric oxide signaling with systolic blood pressure (P interaction=0.76) or diastolic blood pressure (P interaction=0.49) was observed. Similarly, no evidence of an interaction between the NOS3 and GUCY1A3 loci was observed for CHD (P interaction=0.53).
We performed mediation analysis to determine whether the degree to which the change in blood pressure associated with the nitric oxide signaling score explained the protective effect on CHD. Adjustment for the effect on systolic blood pressure led only to a modest attenuation of the association of the nitric oxide signaling genetic score with CHD (OR, 0. Estimates were derived in the UK Biobank using logistic regression, adjusted for age, sex, 10 principal components, and array type, with the exception of chronic kidney disease, which was derived using summary statistics from CKDGen. Estimates for coronary heart disease, diabetes mellitus, and migraine additionally included summary estimates from CARDIOGRAM (Coronary Artery Disease Genome Wide Replication and Meta-Analysis), DIAGRAM (Diabetes Genetics Replication and Meta-Analysis), and IHGC (International Headache Genetics Consortium) and were pooled using inverse variance weighted fixed effects meta-analysis. COPD indicates chronic obstructive pulmonary disease; MAP, mean arterial pressure; OR, odds ratio; PheWAS, phenome-wide association study; and SD, standard deviation. Significant P values are in boldface.
only Data Supplement), suggesting that much of the decrease in CHD risk through increased nitric oxide signaling seems to be through pathways other than blood pressure. Indeed, the effect size of rs3918226 (NOS3) and rs7692387 (GUCY1A3) on CHD deviated substantially from an estimate based on just the systolic blood pressure effects of these variants ( Figure 5) .
In contrast to common variants that promote increased nitric oxide signaling, we sought to test the hypothesis that rare inactivating variants in NOS3 or GUCY1A3 would be associated with increased blood pressure and risk of CHD. Twenty-seven participants with predicted loss-of-function variants in NOS3 or GU-CY1A3 were identified in the T2D GENES study (Table V in the online-only Data Supplement). Presence of a predicted loss-of-function variant in NOS3 or GUCY1A3 was associated with increased systolic blood pressure (22.8 mm Hg; 95% CI, 11.7-33.9; P=5.6*10 -5 , respectively) ( Figure 6 ) and diastolic pressure (9.7 mm Hg; 95% CI 3.5-15.9; P=0.002) ( Figure VI in the online-only Data Supplement). Twenty-seven individuals with predicted loss-of-function variants were identified in Myocardial Infarction Genetics Consortium studies (Table VI in the online-only Data Supplement). Predicted loss-of-function variants in the NOS3-GUCY1A3 pathway were associated with a 3-fold higher risk of CHD (OR, 3.03; 95% CI, 1.29-7.12; P=0.01) (Figure 6 ).
DISCUSSION
A genetic predisposition to enhanced nitric oxide signaling was associated with reduced blood pressure, improved renal and pulmonary function, and significantly reduced risks of CHD (OR, 0.37; 95% CI, 0.31-0.45), peripheral arterial disease (OR, 0.42; 95% CI, 0.26-0.68), and stroke (OR, 0.53; 95% CI, 0.37-0.76). Mediation analysis suggested that this protective effect is mediated only in part by blood pressure-related pathways. In contrast, mutations predicted to truncate NOS3 or GU-CY1A3 are associated with higher blood pressure and a ≈3-fold higher risk of CHD.
These results permit several conclusions. First, stimulation of nitric oxide signaling may prevent atherosclerotic cardiovascular disease. The use of an oral soluble guanylyl cyclase stimulator has proven effective in the treatment of pulmonary hypertension, 13 reinforcing the Figure 5 . Association of common variants in the NOS3 (rs3918226) and GUCY1A3 (rs7692387) loci with systolic blood pressure and coronary heart disease. Solid line represents the estimated effect of systolic blood pressure on coronary heart disease from 54 distinct blood pressure loci from GWAS. A test for heterogeneity comparing the association for the genetic nitric oxide score to other blood pressure loci was significant (P<0.001). Estimates for systolic blood pressure were derived from the UK Biobank with adjustment for age, sex, and 10 principal components.
Estimates for coronary heart disease were derived from inverse variance fixed effects meta-analyses of CARDIOGRAM (Coronary Artery Disease Genome Wide Replication and Meta-Analysis)and the UK Biobank. CHD indicates coronary heart disease; and SBP, systolic blood pressure. A, Estimates for systolic blood pressure and diastolic blood pressure from T2D GENES study (Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples) were derived using linear regression with adjustment for 5 principal components of ancestry. B, Estimates for CHD from the Myocardial Infarction Genetics Consortium were derived using logistic regression, with adjustment for sex, cohort, and 5 principal components of ancestry. CHD indicates coronary heart disease; CI indicates confidence interval; LOF, loss of function; OR, odds ratio; and SBP, systolic blood pressure.
ORIGINAL RESEARCH ARTICLE
potential to target this pathway using a small-molecule approach. The 63% and 58% reductions in CHD and peripheral arterial disease, respectively, observed in this study are likely to be of greater magnitude than what would be observed in a randomized trial of a nitric oxide signaling stimulator because genetic estimates represent the effect of increased nitric oxide signaling over a lifetime rather than an intervention later in life and for a more limited duration. 23 However, the significant and large risk reductions in cardiovascular disease observed in this study lend support to efforts to target nitric oxide signaling in the prevention or treatment of atherosclerotic cardiovascular disease. 1, 24, 25 Second, stimulation of nitric oxide signaling may represent a pathway for CHD prevention that is independent of current approaches. A genetic predisposition to nitric oxide signaling was not associated with lipid, glycemic, or anthropometric traits. Furthermore, the majority of the reduction in risk of CHD with increased nitric oxide signaling appeared to be independent of the variant's impact on blood pressure. Consistent with these findings, a recent functional characterization of the lead GUCY1A3 variant rs7692387 observed carriers of the risk allele of this variant to have elevated levels of platelet aggregation and increased vascular smooth muscle cell migration on stimulation of soluble guanylyl cyclase. 19 Third, these results suggest that stimulation of nitric oxide signaling may improve renal and pulmonary function. A genetic predisposition to enhanced nitric oxide signaling was associated with a higher glomerular filtration rate as determined by either cystatin C or creatinine, a finding that awaits further confirmation in larger studies. Increased nitric oxide signaling was also associated with improved pulmonary function. Although medications to stimulate nitric oxide signaling are effective and approved for treatment of pulmonary hypertension, 1, 13 these results suggest that the stimulation of nitric oxide signaling may prove useful for other populations with reduced pulmonary function.
Our study has several limitations. First, we used common variants in the GUCY1A3 and NOS3 loci to estimate the phenotypic effects of increased nitric oxide signaling. It is possible that these variants may be in linkage disequilibrium with other variants that have phenotypic effects independent of nitric oxide-signaling pathways. However, the common variants were associated with direct measurement of GUCY1A3 and NOS3 expression in vascular and pulmonary tissues, and we observed consistent effects of rare predicted loss-of-function variants in GUCY1A3 and NOS3 on blood pressure and CHD, suggesting that the common variants mediated their effects through the NOS3-GUCY1A3 nitric oxide-signaling pathway. Second, the phenome-wide association study to determine the full spectrum of associations in the UK Biobank may have been underpowered to detect associations for some diseases. Third, our rare variant analysis was restricted to variants predicted to lead to loss of NOS3 or GU-CY1A3 function; the prevalence of missense mutations that impair the NOS3-GUCY1A3 pathway may be much larger than the prevalence of rare predicted lossof-function variants observed in this study. Finally, the majority of participants in this study were of European ancestry, and, as such, these observations need validation in ancestries outside of Europe because ethnic differences in nitric oxide-mediated responses have been previously reported. 26 In conclusion, a genetic predisposition to enhanced nitric oxide signaling was associated with reduced risks of CHD and peripheral arterial disease and improved renal and pulmonary function. Stimulation of nitric oxide signaling may prove useful for the prevention and treatment of a range of diseases. 
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